Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer
Journal for ImmunoTherapy of Cancer · 2024
DOI: 10.1136/jitc-2024-009677 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Nicolas Zhou und 36 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Nahyan Foundation, Bob Mayberry Foundation.
Abstract (Originalsprache)
Background
Neoadjuvant immune checkpoint inhibitors (ICIs) have improved survival outcomes compared with chemotherapy in resectable non-small cell lung cancer (NSCLC). However, the impact of actionable genomic alterations (AGAs) on the efficacy of neoadjuvant ICIs remains unclear. We report the influence of AGAs on treatment failure (TF) in patients with resectable NSCLC treated with neoadjuvant ICIs.
Methods
Tumor molecular profiles were obtained from patients with stage I–IIIA resectable NSCLC (American Joint Committee on Cancer seventh edition) treated with either neoadjuvant nivolumab (N, n=23) or nivolumab+ipilimumab (NI, n=21) followed by surgery in a previously reported phase-2 randomized study ( NCT03158129 ). TF was defined as any progression of primary lung cancer after neoadjuvant ICI therapy in patients without surgery, radiographic and/or biopsy-proven primary lung cancer recurrence after surgery, or death from possibly treatment-related complications or from primary lung cancer since randomization. Tumors with AGAs (n=12) were compared with tumors without AGAs and non-profiled squamous cell carcinomas (non-AGAs+NP SCC, n=20).
Results
With a median follow-up of 60.2 months, the overall TF rate was 34.1% (15/44). Tumor molecular profiling was retrospectively obtained in 47.7% (21/44) of patients and select AGAs were identified in 12 patients: 5 epidermal growth factor receptor (EGFR) , 2 KRAS , 1 ERBB2 , and 1 BRAF mutations, 2 anaplastic lymphoma kinase (ALK) and 1 RET fusions. The median time to TF in patients with AGAs was 24.7 months (95% CI: 12.6 to 40.4), compared with not reached (95% CI: not evaluable (NE)–NE) in the non-AGAs+NP SCC group. The TF risk was higher in AGAs (HR: 5.51, 95% CI: 1.68 to 18.1), and lower in former/current smokers (HR: 0.24, 95% CI: 0.08 to 0.75). The odds of major pathological response were 4.71 (95% CI: 0.49 to 45.2) times higher in the non-AGAs+NP SCC group, and the median percentage of residual viable tumor was 72.5% in AGAs compared with 33.0% in non-AGS+NP SCC tumors.
Conclusions
Patients with NSCLC harboring select AGAs, including EGFR and ALK alterations, have a higher risk for TF, shorter median time to TF, and diminished pathological regression after neoadjuvant ICIs. The suboptimal efficacy of neoadjuvant chemotherapy-sparing, ICI-based regimens in this patient subset underscores the importance of tumor molecular testing prior to initiation of neoadjuvant ICI therapy in patients with resectable NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Thoracic and Head and Neck Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA TCascone@MDAnderson.org william.william@medicos.oncoclinicas.com.
- Grupo Oncoclínicas, Sao Paulo, Brazil.
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Nicolas Zhou, Jianjun Zhang, Mehmet Altan, J Jack Lee, Marcelo V Negrao, Tina Cascone
Förderung
- NCI NIH HHS
- Nahyan Foundation
- Bob Mayberry Foundation
- MD Anderson Cancer Center Physician Scientist Program
- Rexanna’s Foundation for Fighting Lung Cancer
- NIH/NCI
- Khalifa Bin Zayed Al Nahyan Foundation
- Andrew Sabin Family Foundation
Zitieren
APA
Zhou, N., Leung, C. H., William, W. N., Weissferdt, A., Pataer, A., Godoy, M. C. B., Carter, B. W., Fossella, F. V., Tsao, A. S., Blumenschein, G. R., Le, X., Zhang, J., Skoulidis, F., Kurie, J. M., Altan, M., Lu, C., Glisson, B. S., Byers, L. A., Elamin, Y. Y., …, & Cascone, T. (2024). Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-009677
Vancouver
Zhou N, Leung CH, William WN, Weissferdt A, Pataer A, Godoy MCB, et al. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2024-009677
BibTeX
@article{Zhou2024,
author = {Zhou, Nicolas and Leung, Cheuk H and William, William N and Weissferdt, Annikka and Pataer, Apar and Godoy, Myrna C B and Carter, Brett W and Fossella, Frank V and Tsao, Anne S and Blumenschein, George R and Le, Xiuning and Zhang, Jianjun and Skoulidis, Ferdinandos and Kurie, Jonathan M and Altan, Mehmet and Lu, Charles and Glisson, Bonnie S and Byers, Lauren A and Elamin, Yasir Y and Mehran, Reza J and Rice, David C and Walsh, Garrett L and Hofstetter, Wayne L and Roth, Jack A and Tran, Hai T and Wu, Jia and Solis Soto, Luisa M and Kadara, Humam and Swisher, Stephen G and Vaporciyan, Ara A and Gibbons, Don L and Lin, Heather Y and Lee, J Jack and Heymach, John V and Negrao, Marcelo V and Sepesi, Boris and Cascone, Tina},
title = {Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
doi = {10.1136/jitc-2024-009677}
}
EUVIMED